| Autor: |
Bank PCD; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, Netherlands.; Leiden Network for Personalised Therapeutics, Leiden University Medical Center, Leiden, Netherlands., Swen JJ; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, Netherlands. j.j.swen@lumc.nl.; Leiden Network for Personalised Therapeutics, Leiden University Medical Center, Leiden, Netherlands. j.j.swen@lumc.nl., Schaap RD; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, Netherlands.; Leiden Network for Personalised Therapeutics, Leiden University Medical Center, Leiden, Netherlands., Klootwijk DB; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, Netherlands.; Leiden Network for Personalised Therapeutics, Leiden University Medical Center, Leiden, Netherlands., Baak-Pablo R; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, Netherlands.; Leiden Network for Personalised Therapeutics, Leiden University Medical Center, Leiden, Netherlands., Guchelaar HJ; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, Netherlands.; Leiden Network for Personalised Therapeutics, Leiden University Medical Center, Leiden, Netherlands. |
| Abstrakt: |
Despite the nationwide availability of pharmacogenomic (PGx) guidelines in electronic medication surveillance systems in The Netherlands, PGx guided prescribing is still uncommon in primary care. We set out to investigate the adoption of pharmacist initiated PGx testing in primary care. Community pharmacists were offered a free PGx test covering 40 variants in 8 genes to test patients receiving an incident prescription (IRx) of a selection of 10 drugs. Results of the PGx test along with predicted phenotypes and a therapeutic recommendation based on the Dutch Pharmacogenetics Working Group (DPWG) guidelines were transferred to the pharmacist and physician. Adoption was defined as the percentage of eligible patients that received genotyping. From November 2014-July 2016, 200 patients were included with an adoption of 18.0%. Of the included patients 57.5% received an IRx for atorvastatin, 14.5% started with simvastatin and 28.0% received an IRx for amitriptyline, (es)citalopram, nortriptyline, or venlafaxine. 90% of the patients carried at least one actionable PGx test result in the selected PGx-panel. In 31.0% of the incident prescriptions a combination between a drug with a known gene-drug interaction and an actionable genotype was present and a therapeutic recommendation was provided. The provided recommendations were accepted by the clinicians in 88.7% of the patients. Pharmacist initiated implementation of PGx in primary care is feasible, and the frequency of actionable gene-drug interactions for the selected drugs is high. |
Full text from SpringerLink